Hepion Pharmaceuticals Inc
hepionpharma.comWhat Do They Do?
Holds licenses to diagnostic tests for celiac disease, respiratory infections, H. pylori and liver disease.
10-K for FY2025, filed Mar 12, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2023, filed Apr 16, 2024
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$1.2MView ↗
- ▲ +20% (Loss)
- vs −$1M in Q2 FY2025
-
Mar 18, 2026
CEO resigns; interim CEO appointed
The CEO resigned for personal reasons, and the board appointed Gary Stetz interim CEO.
Sources
8-K, filed Mar 18, 2026
On March 16, 2026, Dr. Kaouthar Lbiati, the Chief Executive Officer of Hepion Pharmaceuticals, Inc. (the “Company”) informed the Board of…View ↗
From drug candidate to diagnostics
The older report centers on developing rencofilstat for liver disease; the latest describes Hepion as a medical diagnostics company, licenses diagnostic tests, and says it transferred rencofilstat assets to Panetta.
10-K for FY2022, filed Apr 10, 2023 10-K for FY2025, filed Mar 12, 2026We are a biopharmaceutical company headquartered in Edison, New Jersey, focused primarily on the development of drug therapy for treatment…View ↗
Hepion Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Morristown, New Jersey, that was previously…View ↗
On May 9, 2025, we entered into a license agreement (“License Agreement”) with New Day Diagnostics LLC (“New Day”) pursuant to which we…View ↗
On May 26, 2025, we entered into a patent and associated assets acquisition agreement (the “Agreement”) with Panetta Partners Limited…View ↗
Loading...
